Athersys announces funding for clinical trial in Houston

In partnership with the University of Texas Health Science Center at Houston, Cleveland biotechnology company Athersys Inc. (NASDAQ: ATHX) plans to conduct a Phase 2 clinical trial evaluating its MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury, according to a news release.

Click here to read the complete article. Story excerpt provided by Crain’s Cleveland Business. Written by Lydia Coutré. Originally published May 2, 2018.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: